Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation, and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation, and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamiparib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Chondrosarcoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Leiomyosarcoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Uterine cancer
  • Focus First in man; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 18 Nov 2021 Results (Data cut off date: September 3, 2019) assessing the dose-escalation/dose-expansion and evaluating the outcomes of pamiparib in patients with advanced solid tumours, published in the British Journal of Cancer.
    • 27 Jan 2020 Status changed from active, no longer recruiting to completed.
    • 12 Nov 2019 According to a BeiGene media release, data to be presented in 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top